PofoliaShared via Pofolia

Journal of the American Society of Nephrology· 2015Q1

Subclinical Rejection Phenotypes at 1 Year Post-Transplant and Outcome of Kidney Allografts

Alexandre Loupy, Déwi Vernerey, Claire Tinel, Olivier Aubert et al.

Short summary

Subclinical antibody-mediated rejection (ABMR) at 1 year post-kidney transplant independently predicts a 3.5-fold increase in graft loss, while subclinical T cell-mediated rejection (TCMR) has a less severe impact.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Subclinical ABMR at 1 year post-transplant is linked to significantly worse long-term kidney allograft survival.
  • Graft survival at 8 years was 56% for subclinical ABMR, 88% for subclinical TCMR, and 90% for no rejection.
  • Subclinical ABMR independently predicted a 3.5-fold increased risk of graft loss in a multivariate model.
  • Subclinical ABMR was associated with faster progression to transplant glomerulopathy.

AI-generated from the title and abstract; the full text is not read.

Abstract

Kidney allograft rejection can occur in clinically stable patients, but long-term significance is unknown. We determined whether early recognition of subclinical rejection has long-term consequences for kidney allograft survival in an observational prospective cohort study of 1307 consecutive nonselected patients who underwent ABO-compatible, complement-dependent cytotoxicity-negative crossmatch kidney transplantation in Paris (2000-2010). Participants underwent prospective screening biopsies at 1 year post-transplant, with concurrent evaluations of graft complement deposition and circulating anti-HLA antibodies. The main analysis included 1001 patients. Three distinct groups of patients were identified at the 1-year screening: 727 (73%) patients without rejection, 132 (13%) patients with subclinical T cell-mediated rejection (TCMR), and 142 (14%) patients with subclinical antibody-mediated rejection (ABMR). Patients with subclinical ABMR had the poorest graft survival at 8 years post-transplant (56%) compared with subclinical TCMR (88%) and nonrejection (90%) groups (P<0.001). In a multivariate Cox model, subclinical ABMR at 1 year was independently associated with a 3.5-fold increase in graft loss (95% confidence interval, 2.1 to 5.7) along with eGFR and proteinuria (P<0.001). Subclinical ABMR was associated with more rapid progression to transplant glomerulopathy. Of patients with subclinical TCMR at 1 year, only those who further developed de novo donor-specific antibodies and transplant glomerulopathy showed higher risk of graft loss compared with patients without rejection. Our findings suggest that subclinical TCMR and subclinical ABMR have distinct effects on long-term graft loss. Subclinical ABMR detected at the 1-year screening biopsy carries a prognostic value independent of initial donor-specific antibody status, previous immunologic events, current eGFR, and proteinuria.

The authors' abstract, as published at the source. Journal of the American Society of Nephrology, 2015 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Transplantation

TransplantationMedicine